Table 3

Multivariable model HRs for time to overall treatment failure, treatment failure because of inadequate seizure control and treatment failure because of unacceptable adverse events, by prognostic factor

Overall HR (95% CI)Inadequate seizure control HR (95% CI)Unacceptable adverse events HR (95%CI)
Treatment history
 Treatment naive1.001.001.00
 Seizures after remission2.05 (1.17 to 3.60)0.53 (0.12 to 2.28)2.42 (1.13 to 5.18)
 Taking non-SANAD AED1.10 (0.71 to 1.71)2.02 (1.13 to 3.60)0.72 (0.35 to 1.49)
EEG result
 Normal1.001.001.00
 Not done2.37 (1.38 to 4.05)1.83 (0.68 to 4.95)1.88 (0.90 to 3.89)
 Non-specific abnormality0.87 (0.52 to 1.47)1.23 (0.51 to 2.98)0.87 (0.44 to 1.74)
 Epileptiform abnormality1.13 (0.82 to 1.56)1.98 (1.12 to 3.52)0.85 (0.56 to 1.29)
Seizure type
 Generalised tonic-clonic seizures only1.001.001.00
 Absence seizures1.55 (1.07 to 2.25)3.36 (1.98 to 5.72)0.70 (0.39 to 1.27)
 Myoclonic or absence seizures with tonic-clonic seizures1.47 (1.04 to 2.08)2.03 (1.17 to 3.52)1.06 (0.64 to 1.76)
 Unclassified tonic-clonic seizures1.14 (0.79 to 1.63)1.09 (0.57 to 2.08)1.20 (0.75 to 1.91)
 Other seizures1.84 (1.13 to 3.00)1.92 (0.84 to 4.39)1.53 (0.78 to 3.00)
Treatment
 Valproate1.001.001.00
 Lamotrigine1.34 (0.98 to 1.83)2.14 (1.33 to 3.46)0.76 (0.47 to 1.23)
 Topiramate1.77 (1.32 to 2.39)1.76 (1.07 to 2.88)1.59 (1.06 to 2.38)
  • SANAD, Standard and New Antiepileptic Drug.